M3 muscarinic receptor Inhibitors
3 drugsAbout M3 muscarinic receptor
The M3 muscarinic receptor is a G protein-coupled receptor activated by acetylcholine, mediating smooth muscle contraction and glandular secretions. As a key member of the muscarinic acetylcholine receptor family, it initiates intracellular signaling cascades upon activation. This makes it a significant target for drug development.
Currently, there is no genetic evidence directly linking M3 receptor variations to specific diseases. However, its involvement in smooth muscle contraction and glandular secretions makes it relevant to conditions affecting these systems.
Three FDA-approved drugs target the M3 receptor: SPIRIVA, DARIFENACIN, and ANORO ELLIPTA. All three drugs are small molecules, with applications spanning respiratory diseases (2 drugs) and other therapeutic areas.
Top M3 muscarinic receptor Drugs
The competitive landscape includes three companies with approved drugs: MACLEODS PHARMS LTD, GSK, and Boehringer Ingelheim.
Low market concentration suggests moderate entry barriers, but established players have a strong foothold.
M3 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
M3 muscarinic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing therapies.
M3 muscarinic receptor Clinical Trials 157 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M3 muscarinic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 19 | 17 | 1 | 1 | 94% |
| Phase 2 | 31 | 25 | 4 | 2 | 86% |
| Phase 3 | 54 | 50 | 3 | 1 | 94% |
| Phase 4 | 53 | 44 | 6 | 3 | 88% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M3 muscarinic receptor Drug Approval Timeline (2004 - 2017)
The first drug was approved in 2004 (SPIRIVA), with the most recent approval in 2017 (DARIFENACIN), spanning 14 years.
The approval timeline indicates a mature target, suggesting limited whitespace for new M3-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 54 (26 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M3 muscarinic receptor. A trial counts if an approved drug acting on M3 muscarinic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.